Blog
What Is Retatrutide? A Research-Backed Guide to the First Triple Agonist
What Is Retatrutide? A Research-Backed Guide to the First Triple Agonist
Choice Peptide Labs | 13 min read | NEJM, Lancet, Springer | June 2026
Retatrutide is the first compound to activate three hormone receptors simultaneously — GIP, GLP-1, and glucagon. Its Phase 2 trial reported weight reduction of up to 24.2% at the highest dose.
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational, once-weekly, triple hormone receptor agonist developed by Eli Lilly. It simultaneously activates GIP, GLP-1, and glucagon receptors. No previously studied peptide had achieved this triple activation in a single molecule.
Source: Jastreboff, A.M., et al. NEJM, 389(6), 514–526. NEJM
Why Three Receptors Instead of Two?
GLP-1 Receptor
- Stimulates insulin, suppresses glucagon, slows gastric emptying, signals satiety
GIP Receptor
- Enhances insulin through a complementary pathway, independent appetite effects in the brain
Glucagon Receptor (The Innovation)
- Hepatic energy expenditure: Increases fat oxidation in the liver
- Lipolysis: Promotes breakdown of stored fat for energy
- Thermogenesis: Contributes to heat production in brown adipose tissue
- The missing piece: GIP and GLP-1 reduce intake. Glucagon increases expenditure.
Phase 2 Trial: The NEJM Results
Randomized, double-blind, placebo-controlled. 48 weeks. Adults with obesity.
| Dose | Weight Reduction at 48 Weeks |
|---|---|
| Placebo | 2.1% |
| 1 mg | 8.7% |
| 4 mg | 17.3% |
| 8 mg | 22.8% |
| 12 mg | 24.2% |
Weight loss curves had not plateaued at 48 weeks, suggesting longer treatment may produce greater effects.
Source: Jastreboff, A.M., et al. NEJM, 389(6), 514–526. NEJM
Phase 1 Data
Published in The Lancet. Confirmed triple receptor activation is achievable in humans. Established safety profile supporting Phase 2 advancement.
Source: Coskun, T., et al. The Lancet. Lancet
Retatrutide vs. Dual Agonists
| Feature | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Receptors | GIP + GLP-1 + Glucagon | GIP + GLP-1 | GLP-1 only |
| Max weight reduction (Phase 2) | 24.2% | ~22.5% | ~14.9% |
| Unique mechanism | Hepatic energy expenditure | Dual incretin | Single receptor |
| Status | Phase 3 (ongoing) | Approved (2022) | Approved (2017/2021) |
The Science of Glucagon
- Hepatic fat oxidation: Activates beta-oxidation in the liver
- Thermogenesis: Increases heat production in brown adipose tissue
- Lipid metabolism: Promotes breakdown of stored triglycerides
A 2025 Springer review described triple agonism as “a promising next step” in metabolic research.
Source: “Triple Agonism Based Therapies for Obesity.” Springer, 2025. Springer
Retatrutide in Plain English
Your body manages weight two ways:
- Energy in — how much you eat (appetite hormones)
- Energy out — how much you burn (metabolism and fat oxidation)
Most compounds target energy in. Retatrutide targets both: appetite suppression through GIP + GLP-1, and increased fat burning through glucagon.
Frequently Asked Questions
What makes retatrutide different from tirzepatide?
Tirzepatide: GIP + GLP-1 (two receptors). Retatrutide: GIP + GLP-1 + glucagon (three). The glucagon receptor targets hepatic energy expenditure and fat oxidation.
What were the Phase 2 results?
24.2% mean weight reduction at 12mg over 48 weeks. Dose-response: 8.7% (1mg), 17.3% (4mg), 22.8% (8mg), 24.2% (12mg).
Why does glucagon matter?
It increases energy expenditure through fat oxidation, thermogenesis, and lipolysis — the other side of the energy balance equation.
Is retatrutide FDA-approved?
No. Phase 3 trials are ongoing. Not approved for any medical indication.
Has weight loss plateaued?
No. Curves had not plateaued at 48 weeks. Phase 3 is testing longer durations.
Who developed it?
Eli Lilly (LY3437943). Same company as tirzepatide/Mounjaro.
Explore Retatrutide from Choice Peptide Labs
10mg vial · Published COA · USA-stocked · Cold-chain shipped
Disclaimer: For educational purposes only. Retatrutide is investigational and not FDA-approved. All products from Choice Peptide Labs are for laboratory research use only.
